A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 1, 2005, Pages 26-30

  Markman, Maurie ^a,b   Belinson, Jerome ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Interval surgical cytoreduction; Intraperitoneal chemotherapy; Neoadjuvant chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; IRINOTECAN; PACLITAXEL; PLATINUM;

ABDOMINAL CANCER; ADJUVANT CHEMOTHERAPY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOATING; CARCINOMATOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; FEMALE; HUMAN; LAPAROTOMY; MULTIMODALITY CANCER THERAPY; OVARY ADENOCARCINOMA; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; ADJUVANT THERAPY; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; MULTIPLE CYCLE TREATMENT; TUMOR BIOPSY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; SECOND-LOOK SURGERY; TREATMENT OUTCOME;

EID: 11244317227     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0624-1     Document Type: Article

References (30)

1. Ansquer V, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, Lhomme C, Scherer C, Tigaud J-D, Benchaib M, Fourme E, Castaigne D, Querleu D, Dargent D (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. Cancer 91:2329-2334
2. Barakat RR, Almadrones L, Venkatraman ES, Aghajanian C, Brown C, Shapiro F, Curtin JP, Spriggs D (1998) A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 69:17-22
3. Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D (2002) Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 20:694-698
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248-1259
5. Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr (1983) Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep 67:235-238
6. Chan YM, Ng TY, Ngan HYS, Wong LC (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88:9-16
7. Covens AL (2000) A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78:269-274
8. DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI (1986) Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18:235-238
9. Eisenkop SM, Friedman RL, Wang H-J (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69:103-108
10. Elferink F, van der Vijgh WJF, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG (1988) Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:57-60
11. Girling JC, Soutter WP (1996) Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: a topic for debate. Int J Gynecol Cancer 6:81-84
12. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159-166
13. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845-851
14. Kayikciog Lu F, Kose MF, Boran N, Caliskan E, Tulunay G (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11:466-470
15. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, Hundelshausen B von, Pachyn D, Ulm K, Graeff H (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 2585-2591
16. Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS (2002) The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 85:351-355
17. Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG (1989) Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380-3384
18. Los G, Mutsaers PHA, Lenglet WJM, Baldew GS, McVie JG (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25:389-394
19. Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277-283
20. Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W (1991) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805
21. Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W (1992) Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10:1479-1484
22. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6
23. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC (1995) Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 165:875-878
24. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18:106-115
25. Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD (1983) Pharmacokinetics of ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67:1085-1092
26. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH (2002) A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 21:201a
27. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72:93-99
28. Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, Alberts D (1996) Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 6:356-361
29. van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S, for the Gynecological Cooperative Group of the European Organization for Research and Treatment of Cancer (1995) N Engl J Med 332:629-634
30. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71:431-436